	O/SB/08B (07-05
Approved for use through 07/31/2006	. OMB 0651-003

Un	ndesthe Paperwork Red	duction A	ct of 1995, no persons a	o.s. Patent re required to respond to a collection	of information unless it contains a valid OMB control	number.
Substitut	to form 1449/PTO				August 11, 2006  d Inventor SOREQ, Hermona et al.  1656  ame S. Noakes	
	2 101 101111 1440/1 10			Application Number	10/589,116	
INF	ORMATION	I DIS	CLOSURE	Filing Date	August 11, 2006	
STA	ORMATION DISCLOSURE ATEMENT BY APPLICANT  (Use as many sheets as necessary)	First Named Inventor	SOREQ, Hermona et al.			
		Art Unit	1656			
	(Use as many sheets as necessary)			Examiner Name	S.Noakes	
Sheet 1 of 8		Attorney Docket Number	7640-X06-063			

	<del>-</del>	NON PATENT LITERATURE DOCUMENTS	<del>,</del>
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	ABO, T. and KAWAMURA, T., Ther. Apher., 2002, pp.348-357, vol.6.	
	AB	ABRAMSON, N. and MELTON, B., Am. Fam. Physician, 2000, pp.2053-2060., vol.62.	
	AC	BASSER, R.L. et al., Blood, 2002, pp.2599-2602, vol.99.	
	AD	BASSINI, A. et al., Blood, 1999, pp.1178-1188, vol.93.	
	AE	BIRIKH, K.R. et al, RNA Society, 1997, pp.429-437, vol.3.	
	AF	BOROVIKOVA, L.V. et al., Nature, 2000, pp.458-462, vol.405.	
	AG	BRENNER et al., FASEB J, 2003, pp.214-22, vol.17(2).	
	АН	BUSSLINGER, M., Ann. Rev. Immunol., 2004, pp.55-79, vol.22.	
	Al	CHAN, R.Y.Y. et al., J. Biol. Chem., 1998, pp.9727-9733, vol.273.	
	AJ	CRAIG, W. et al., Br. J. Haematol, 1994, pp.24-30, vol.88.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449/PTO  INFORMATION DISCLOSURE		Complete if Known		
Substitu			<b>9</b> *	Application Number	10/589,116
INF	ORMATION	DIS	CLOSURE	Filing Date	Feb 10,2005
STA	STATEMENT BY APPLICAN			First Named Inventor	SOREQ, Hermona et al.
	(Use as many she	-4		Art Unit	
	Ose as many sne	ets as n	recessary)	Examiner Name	
Sheet	2	of	8	Attorney Docket Number	7640-X06-063

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AK .	DELGADO, I. et al., Gynecol. Obstet. Invest., 1994, pp.227-235, vol.38.	
	AL	DEUTSCH, V. et al., Exp. Hematol., 2002, pp.1153-1161, vol.30.	
	АМ	ERB, C. et al., J. Neurochem., 2001, pp.638-646, vol.77.	
	AN	FLORES-FLORES, C. et al., J. Neural Transm., 2002, pp.165-179, vol.62(supp).	
	AO	GAINSFORD, T. et al., Blood, 2000, pp.528-534, vol.95.	
	AP	GRISARU, D. et al., Mol. Cell Biol., 1999, pp.788-795, vol.19.	
	AQ	GRISARU, D. et al., Molecular Medicine, 2001, pp.93-105, vol.7.	
	AR	GUENECHEA, G. et al., Blood, 1999, pp.1097-1105, vol.93.	
	AS	HANADA and YOSHIMURA, Cytokine Growth Factor Rev., 2002, pp.413-421, vol.13.	
	AT	HELLSTROM-LINDAHL, E. and NORDBERG, A., J. Neuroimmunol., 1996, pp.139-144, vol.68.	

		· · · · · · · · · · · · · · · · · · ·
Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	ite for form 1449/PTO		10 10 10 persons at	Complete if Known			
Substitu	10 10 10 11 1449/210			Application Number	10/589,116		
INF	ORMATION	1 DÍS	SCLOSURE	Filing Date	August 11, 2006		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.		
	//			Art Unit			
	(Use as many sh	eets as i	necessary)	Examiner Name			
Sheet	3	of	8	Attorney Docket Number	7640-X06-063		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AU	ISHIBASHI, T. et al., Proc. Natl. Acad. Sci. U.S.A., 1989, pp.5953-5957, vol.86.	
	AV	JACKSON, C.W., Blood, 1973, pp.413-421, vol.42.	
	AW	JOHNSSON, B. et al., Anal. Biochem., 1991,pp.268-77, vol.198.	
	AX	KANAMARU, S. et al, Stem Cells, 2000, pp.190-195, vol.18.	
	AY	KASER, A. et al., Blood, 2001, pp.2720-2725, vol.98.	
	AZ	KAWASHIMA, K. and FUJI, T., Pharmacol Ther., 2000, pp.29-48, vol.86.	
	ВА	KIECOLT-GLASER, J.K. et al., Proc. Natl. Acad. Sci. U.S.A., 2003, pp.9090-9095, vol.100.	
	BB	KUTER, D.J., Transfusion, 2002, pp.279-283, vol.42.	
	вс	LAGASSE, E. and WEISSMAN, I.L., J. Immunol. Methods, 1996, pp.139-150, vol.197.	
	BD	LEV-LEHMAN, E. et al., Blood, 1997, pp.3644-3653, vol.89.	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known
Qubstitut	S 10/10/11/14/3// 10		• *	Application Number	10/589,116
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)  Filing Date August 11, 2006  SOREQ, Hermona et al.  Art Unit Examiner Name					
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.
				Art Unit	
	(Use as many she	ets as n	ecessary)	Examiner Name	
Sheet	4	of	8	Attorney Docket Number	7640-X06-063

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), tit the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-in number(s), publisher, city and/or country where published.				
•	BE	LI, K. et al., Br. J. Haematol., 1999, pp.178-185, vol.104.			
	BF	LI, Y. et al., J. Neurosci., 2000, pp.149-155, vol.20.			
	BG	MARCHISIO, M. et al., Anat. Rec., 1999, pp.7-14, vol.255.			
	вн	MASTORAKOS, G. and ILIAS, I., Ann. NY Acad. Sci., 2000, pp.95-106, vol.900.			
	ВІ	MILLER, G.E. et al., Health Psychol., 2002, pp.531-41, vol.21.			
	BJ	MITA, Y. et al., Eur. J. Pharmacol., 1996, pp.121-127, vol.297.			
	ВК	NAGATA, Y. et al., Thromb. Haemost., 1997, pp.808-814, vol.77.			
	BL	NAKASHIMA, K. et al., Semin Hematol., 1998, pp.210-221, vol.35.			
	ВМ	NITSCHE, A. et al., Haematologica, 2001, pp.693-699, vol.86.			
	BN	OSHEVSKI, S. et al., Biochem. Biophys. Res. Commun., 1999, pp.603-609, vol.263.			

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB contains.

	te for form 1449/PTO	JCGOIT 75	ct or 1995, no persone an		Complete if Known	1
Substitu	tte for form 1449/P1O			Application Number	10/589, 116	
INF	ORMATION	DIS	CLOSURE	Filing Date	August 11, 2006	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.	
				Art Unit		
	(Use as many she	ets as n	ecessary)	Examiner Name		
Sheet	5	of	8	Attorney Docket Number	7640-X06-063	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	во	PERRY, C. et al., Neoplasia, 2004, pp.279-86, vol.6(3).	
	BP	PICK, M. et al., Br. J. Haematol., 1998, pp.639-650, vol.103.	
	BQ	PICK, M. et al., Ann. NY Acad. Sci., 2004, pp.85-95, vol.1018.	
	BR	PICK, M. et al., Exp. Hematol., 2002, p.1079, vol.30.	
. "	BS	PORCELLINI, A. et al., Int. J. Cell Cloning, 1983, pp.92-104, vol.1.	
	ВТ	RACKE, F.K. et al., J. Biol. Chem., 2001, pp.522-528, vol.276.	
	BU	REIZENSTEIN, P., Br. J. Haematol., 1979, pp.329-334, vol.43.	
	BV	ROJNUCKARIN, P. et al., Blood, 2001, pp.154-161, vol.97.	
	BW	ROJNUCKARIN, P. et al., J. Biol. Chem., 2001, pp.41014-41022, vol.276.	
	вх	SKLAN, E.H. et al., Proc. Natl. Acad. Sci. U.S.A., 2004, pp.5512-5517, vol.101(15).	

			p
Examiner	,	Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

	ite for form 1449/PTO	uçuğii Ai	ty.	e required to respond to a conection	t and Trademark Office; U.S. DEPARTMENT OF COMMERCE to of information unless it contains a valid OMB control number.  Complete if Known
Substitu	ne 101 101111 1445/F10		lş	Application Number	10/589,116
INF	ORMATION	DIS	CLOSURE	Filing Date	August 11, 2006
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.
	(Han an many abo	-4		Art Unit	
	(Use as many she	eis as n	ecessary)	Examiner Name	
Sheet	6	of	8	Attorney Docket Number	7640-X06-063

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	BY	SOREQ, H. and SEIDMAN, S., Nat. Rev. Neurosci., 2001, pp.294-302, vol.2.	
	BZ	STERNFELD, M. et al., J. Neurosci., 1998, pp.1240-1249, vol.18.	
	CA	STERNFELD, M. et al., J. Physiol. Paris, 1998, pp.249-255, vol.92.	
	СВ	STERNFELD, M. et al., Proc. Natl. Acad. Sci. U.S.A., 2000, pp.8647-8652, vol.97.	
	СС	STOWE, R. P. et al., J. Leukoc. Biol., 1999, pp.179-186, vol.65.	
	CD	SZELENYI et al., Immunol. Letter, 1987, pp.49-54, vol.16.	
	CE	SZELENYI et al., Br. J. Haematol., 1982, pp.241-5, vol.50.	
	CF	TAVASSOLI, M., Blood Cells, 1991, pp.269-281, vol.17.	
	CG	TERAMURA, M. et al., Cancer Chemother. Pharmacol., 1996, pp.S99-102, vol.38(supp).	
	сн	TOFT, P. et al., Apmis, 1994, pp.43-48, vol.102.	

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449/PTO			Complete if Known		
Gubattut	10/10/11/14/3//10			Application Number	10/589,116	
INFO	DRMATION	DIS	CLOSURE	Filing Date	August 11, 2006	
STATEMENT BY APPLICANT		First Named Inventor	SOREQ, Hermona et al.			
	(llas as many sha			Art Unit	·	
	(Use as many she	ets as n	ecessary)	Examiner Name		
Sheet	7	of	8	Attorney Docket Number	7640-X06-063	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CI	TOPILKO and CAILLOU, Blood, 1985, pp.891-5, vol.66.	
	cı	TRACEY, K.J., Nature, 2002, pp.853-9, vol.420.	
	СК	TUIMALA, R. et al., Br. J. Obstret. Gynecol., 1976, pp.707-710, vol.83.	
,	CL	WANAHITA, A. et al., Clin. Infect. Dis.,2002, pp.1585-1592, vol.34.	
	СМ	WANG, H. et al., Nature, 2003, pp.384-388, vol.421.	
	CN	WILSON et al., J. Am. Geriatr. Soc., 2002, pp.2041-2056, vol.50.	
	со	XU, Z. and WEISS, A., Nat. Immunol., 2002, pp.764-71, vol.3.	
	СР	ZAHOREC, R., Bratisl. Lek. Listy., 2001, pp.5-14, vol.102.	
	cq	ZHANG, X.J. et al., Cell Death Differ., 2002, pp.790-800, vol.9.	
	CR	DEUTSCH, V. et al., Blood, 2001, p. 73a, vol91 (11 - part1).	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	nder the Paperwork Rec	luction A	ct of 1995, no persons ar		PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number.  Complete if Known
Cubsul	ate 101 101111 1443/1 10			Application Number	10/589,116
INF	ORMATION	DIS	CLOSURE	Filing Date	August 11, 2006
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.
	(1100 00			Art Unit	1656
	(Use as many she	ets as r	ecessary)	Examiner Name	S. Noakes
Sheet	8	of	8	Attorney Docket Number	7640-X06-063

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	cs	International Search Report for PCT/IL05/000185	
	ст	International Prelim Report on Patentability for PCT/IL05/000185	
<del></del>			

Examiner	/Suzanne M. Noakes/	Date	12/18/2009
Signature	/ Sometime in a reconstruction	Considered	12/10/2000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.